Displaying drugs 701 - 725 of 831 in total
Pralnacasan
Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).
Investigational
NP-6A4
NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.
Investigational
Matched Description: … NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). …
Banoxantrone
Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation to significantly delay growth of tumours compared to administration of either banoxantrone or radiation alone. Banoxantrone was also efficacious in...
Investigational
Elsamitrucin
The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)
Investigational
Phthalocyanine
Phthalocyanine is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Investigational
Matched Description: … Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II …
Ferrous chloride
Experimental
Danvatirsen
Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).
Investigational
Matched Description: … Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer …
GW 468816
GW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.
Investigational
Matched Description: … It was undergoing phase II trials since December 2003. …
AVI-4065
AVI-4065, a phosphorodiamidate Morpholino oligomer (PMO), is an investigational antisense HCV drug. It was developed by Sarepta Therapeutics, Inc. After phase II trials it was cancelled due to lack of potency.
Investigational
Matched Description: … After phase II trials it was cancelled due to lack of potency. [L2917] …
Ginsenoside Rb1
Ginsenosides are a class of steroid glycosides, and triterpene saponins, found exclusively in the plant genus Panax (ginseng). Ginsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy. Because ginsenosides appear to affect multiple pathways, their effects are complex...
Nutraceutical
Rineterkib
Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients).
Investigational
Matched Description: … signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II …
Iratumumab
Immunoglobulin G1, anti-(human CD30 (antigen)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer. Molecular weight is approximately 170,000 daltons. In phase I/II clinical trials for treatment of CD30+ lymphomas.
Investigational
Matched Description: … In phase I/II clinical trials for treatment of CD30+ lymphomas. …
Tifuvirtide
Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.
Investigational
Matched Description: … It has received fast-track designation from the FDA and is in Phase I/II clinical testing. …
Bifunctional epoxide hydrolase 2
Bifunctional epoxide hydrolase 2 is under investigation in clinical trial NCT00654966 (Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers).
Investigational
Matched Description: … hydrolase 2 is under investigation in clinical trial NCT00654966 (Evaluation of the Effects of Urotensin-II …
Fleroxacin
Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.
Experimental
Matched Categories: … Topoisomerase II Inhibitors …
Virginiamycin M1
Pristinamycin IIA is a macrolide antibiotic, a member of the streptogramin A group of antibiotics, and one component of pristinamycin. It is produced by Streptomyces graminofaciens and other bacteria.
Experimental
Apadenoson
Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.
Investigational
Matched Description: … It is developed by Bristol-Myers Squibb and is in phase II of clinical trials. …
Interferon Gamma
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Investigational
Matched Description: … Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. …
Nisevokitug
Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients).
Investigational
Matched Description: … transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II …
Amonafide
Amonafide is a substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents.
Investigational
Zotiraciclib
Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma).
Investigational
Matched Description: … NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II …
Alprenolol
One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.
Experimental
Withdrawn
Taberminogene vadenovec
Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs after vascular surgery. The initial target market is haemodialysis graft access surgery, a procedure in which patients whose kidneys have...
Investigational
Matched Description: … EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it …
Displaying drugs 701 - 725 of 831 in total